Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pharmacokinetic Considerations for Antibody-Drug Conjugates against Cancer
Authors
Keywords
antibody-drug conjugate, cancer, mechanistic, pharmacokinetic, tumour
Journal
PHARMACEUTICAL RESEARCH
Volume 34, Issue 12, Pages 2579-2595
Publisher
Springer Nature
Online
2017-09-19
DOI
10.1007/s11095-017-2259-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
- (2017) Hong Li et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis
- (2017) Satyawan B. Jadhav et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Population PBPK modelling of trastuzumab: a framework for quantifying and predicting inter-individual variability
- (2017) Paul R. V. Malik et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Impact of altered endogenous IgG on unspecific mAb clearance
- (2017) Saskia Fuhrmann et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Tumor-Associated Macrophages Can Contribute to Antitumor Activity through FcγR-Mediated Processing of Antibody–Drug Conjugates
- (2017) Fu Li et al. MOLECULAR CANCER THERAPEUTICS
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs)
- (2016) Julia Mantaj et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Cathepsin B Cleavage of vcMMAE-Based Antibody–Drug Conjugate Is Not Drug Location or Monoclonal Antibody Carrier Specific
- (2016) Benson Gikanga et al. BIOCONJUGATE CHEMISTRY
- Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology
- (2016) Yusuke Ogitani et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Antibody-drug conjugates—an emerging class of cancer treatment
- (2016) Nikolaos Diamantis et al. BRITISH JOURNAL OF CANCER
- DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
- (2016) Y. Ogitani et al. CLINICAL CANCER RESEARCH
- Current Status: Site-Specific Antibody Drug Conjugates
- (2016) Dominik Schumacher et al. JOURNAL OF CLINICAL IMMUNOLOGY
- Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics
- (2016) Pamela Thompson et al. JOURNAL OF CONTROLLED RELEASE
- Quantitative characterization of in vitro bystander effect of antibody-drug conjugates
- (2016) Aman P. Singh et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies
- (2016) Patrick M. Glassman et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins
- (2016) Seth H. Pincus et al. JOURNAL OF VIROLOGY
- Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
- (2016) Heather Donaghy mAbs
- Physiologically-based modeling to predict the clinical behavior of monoclonal antibodies directed against lymphocyte antigens
- (2016) Patrick M. Glassman et al. mAbs
- Biodistribution and Targeting of Anti-5T4 Antibody-Drug Conjugate Using Fluorescence Molecular Tomography
- (2016) A. Giddabasappa et al. MOLECULAR CANCER THERAPEUTICS
- RN927C, a Site-Specific Trop-2 Antibody-Drug Conjugate (ADC) with Enhanced Stability, Is Highly Efficacious in Preclinical Solid Tumor Models
- (2016) P. Strop et al. MOLECULAR CANCER THERAPEUTICS
- ABT-414, an Antibody-Drug Conjugate Targeting a Tumor-Selective EGFR Epitope
- (2016) A. C. Phillips et al. MOLECULAR CANCER THERAPEUTICS
- Altering Antibody–Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability
- (2016) Kevin J. Hamblett et al. MOLECULAR PHARMACEUTICS
- Increment in Drug Loading on an Antibody–Drug Conjugate Increases Its Binding to the Human Neonatal Fc Receptor in Vitro
- (2016) Guillaume Brachet et al. MOLECULAR PHARMACEUTICS
- Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
- (2016) David A. Reardon et al. NEURO-ONCOLOGY
- Focused ultrasound induced hyperthermia accelerates and increases the uptake of anti-HER-2 antibodies in a xenograft model
- (2016) Miguel N. Centelles et al. PHARMACOLOGICAL RESEARCH
- Maternal-Foetal Diabetes Modifies Neonatal Fc Receptor Expression on Human Leucocytes
- (2016) E. G. de Souza et al. SCANDINAVIAN JOURNAL OF IMMUNOLOGY
- ImmunoPET helps predicting the efficacy of antibody-drug conjugates targeting TENB2 and STEAP1
- (2016) Simon-Peter Williams et al. Oncotarget
- Extracellular domain shedding influences specific tumor uptake and organ distribution of the EGFR PET tracer 89Zr-imgatuzumab
- (2016) Martin Pool et al. Oncotarget
- Effect of Attachment Site on Stability of Cleavable Antibody Drug Conjugates
- (2015) Magdalena Dorywalska et al. BIOCONJUGATE CHEMISTRY
- The cryptophycins as potent payloads for antibody drug conjugates
- (2015) Vishal A. Verma et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Pharmacokinetic characterization of BMS-936561, an anti-CD70 antibody-drug conjugate, in preclinical animal species and prediction of its pharmacokinetics in humans
- (2015) Haiqing Wang et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Current methods for the synthesis of homogeneous antibody–drug conjugates
- (2015) Alicja M. Sochaj et al. BIOTECHNOLOGY ADVANCES
- A Polymer-Based Antibody-Vinca Drug Conjugate Platform: Characterization and Preclinical Efficacy
- (2015) A. V. Yurkovetskiy et al. CANCER RESEARCH
- Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions
- (2015) Algirdas Grevys et al. JOURNAL OF IMMUNOLOGY
- Effect of microvascular distribution and its density on interstitial fluid pressure in solid tumors: A computational model
- (2015) M. Mohammadi et al. MICROVASCULAR RESEARCH
- Antibody–Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs
- (2015) Christopher R. Behrens et al. MOLECULAR PHARMACEUTICS
- Metabolites of Antibody–Maytansinoid Conjugates: Characteristics and in Vitro Potencies
- (2015) Wayne Widdison et al. MOLECULAR PHARMACEUTICS
- In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab–MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios
- (2015) Penny Bryant et al. MOLECULAR PHARMACEUTICS
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading
- (2015) Pavel Strop et al. NATURE BIOTECHNOLOGY
- Trastuzumab emtansine (T-DM1) renders HER2 + breast cancer highly susceptible to CTLA-4/PD-1 blockade
- (2015) Philipp Müller et al. Science Translational Medicine
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
- (2015) Antoine Maruani et al. Nature Communications
- Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model
- (2015) Félix Gremonprez et al. Oncotarget
- Overview of Methods for Overcoming Hindrance to Drug Delivery to Tumors, with Special Attention to Tumor Interstitial Fluid
- (2015) Gianfranco Baronzio et al. Frontiers in Oncology
- A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design
- (2015) Christina Vasalou et al. PLoS One
- Site-Dependent Degradation of a Non-Cleavable Auristatin-Based Linker-Payload in Rodent Plasma and Its Effect on ADC Efficacy
- (2015) Magdalena Dorywalska et al. PLoS One
- Increased Plasma Colloid Osmotic Pressure Facilitates the Uptake of Therapeutic Macromolecules in a Xenograft Tumor Model
- (2015) Matthias Hofmann et al. NEOPLASIA
- Immunogenicity of Antibody Drug Conjugates: Bioanalytical Methods and Monitoring Strategy for a Novel Therapeutic Modality
- (2014) M. Benjamin Hock et al. AAPS Journal
- Population pharmacokinetics of trastuzumab emtansine (T-DM1), a HER2-targeted antibody–drug conjugate, in patients with HER2-positive metastatic breast cancer: clinical implications of the effect of covariates
- (2014) Dan Lu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
- (2014) H. Uppal et al. CLINICAL CANCER RESEARCH
- Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
- (2014) P. V. Beum et al. JOURNAL OF IMMUNOLOGY
- Site-Specific Trastuzumab Maytansinoid Antibody–Drug Conjugates with Improved Therapeutic Activity through Linker and Antibody Engineering
- (2014) Thomas H. Pillow et al. JOURNAL OF MEDICINAL CHEMISTRY
- Comparative clinical pharmacokinetics of antibody-drug conjugates in first-in-human Phase 1 studies
- (2014) Antoine Deslandes mAbs
- High-content Analysis of Antibody Phage-display Library Selection Outputs Identifies Tumor Selective Macropinocytosis-dependent Rapidly Internalizing Antibodies
- (2014) Kevin D. Ha et al. MOLECULAR & CELLULAR PROTEOMICS
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- Conjugation Effects on Antibody–Drug Conjugates: Evaluation of Interaction Kinetics in Real Time on Living Cells
- (2014) Sina Bondza et al. MOLECULAR PHARMACEUTICS
- Enhanced neonatal Fc receptor function improves protection against primate SHIV infection
- (2014) Sung-Youl Ko et al. NATURE
- Radioimmunoconjugates for the Treatment of Cancer
- (2014) Françoise Kraeber-Bodéré et al. SEMINARS IN ONCOLOGY
- Bevacizumab-Induced Normalization of Blood Vessels in Tumors Hampers Antibody Uptake
- (2013) M. Arjaans et al. CANCER RESEARCH
- Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates
- (2013) Pavel Strop et al. CHEMISTRY & BIOLOGY
- Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood–brain barrier divide
- (2013) Ann-Marie Chacko et al. Expert Opinion on Drug Delivery
- Application of knockout mouse models to investigate the influence of FcγR on the pharmacokinetics and anti-platelet effects of MWReg30, a monoclonal anti-GPIIb antibody
- (2013) Lubna Abuqayyas et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates
- (2013) Michael Ritchie et al. mAbs
- Methods for site-specific drug conjugation to antibodies
- (2013) Christopher R Behrens et al. mAbs
- Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells
- (2013) Cosimo Commisso et al. NATURE
- Preclinical safety profile of trastuzumab emtansine (T-DM1): Mechanism of action of its cytotoxic component retained with improved tolerability
- (2013) Kirsten Achilles Poon et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Bioanalysis of antibody–drug conjugates: American Association of Pharmaceutical Scientists Antibody–Drug Conjugate Working Group position paper
- (2013) Boris Gorovits et al. Bioanalysis
- Tumor Endothelial Cells
- (2013) A. C. Dudley Cold Spring Harbor Perspectives in Medicine
- ADME of Antibody–Maytansinoid Conjugates
- (2012) Hans K. Erickson et al. AAPS Journal
- Compartmental Tissue Distribution of Antibody Therapeutics: Experimental Approaches and Interpretations
- (2012) C. Andrew Boswell et al. AAPS Journal
- Pharmacokinetic mAb–mAb Interaction: Anti-VEGF mAb Decreases the Distribution of Anti-CEA mAb into Colorectal Tumor Xenografts
- (2012) Lubna Abuqayyas et al. AAPS Journal
- Mechanistic Determinants of Biotherapeutics Absorption Following SC Administration
- (2012) Wolfgang F. Richter et al. AAPS Journal
- An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2
- (2012) C Andrew Boswell et al. BRITISH JOURNAL OF PHARMACOLOGY
- A phase 1 study of weekly dosing of trastuzumab emtansine (T-DM1) in patients with advanced human epidermal growth factor 2-positive breast cancer
- (2012) Muralidhar Beeram et al. CANCER
- Cetuximab in combination with anti-human IgG antibodies efficiently down-regulates the EGF receptor by macropinocytosis
- (2012) Christian Berger et al. EXPERIMENTAL CELL RESEARCH
- Application of knockout mouse models to investigate the influence of FcγR on the tissue distribution and elimination of 8C2, a murine IgG1 monoclonal antibody
- (2012) Lubna Abuqayyas et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Drug Transport across the Blood–Brain Barrier
- (2012) William M Pardridge JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification
- (2012) Lambertus A. Peletier et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- A mechanistic compartmental model for total antibody uptake in tumors
- (2012) Greg M. Thurber et al. JOURNAL OF THEORETICAL BIOLOGY
- Subcutaneous bioavailability of therapeutic antibodies as a function of FcRn binding affinity in mice
- (2012) Rong Deng et al. mAbs
- Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates
- (2012) Mauro Acchione et al. mAbs
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
- (2012) C. V. Pastuskovas et al. MOLECULAR CANCER THERAPEUTICS
- The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates
- (2012) H. K. Erickson et al. MOLECULAR CANCER THERAPEUTICS
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- (2012) Ben-Quan Shen et al. NATURE BIOTECHNOLOGY
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interstitial Fluid and Lymph Formation and Transport: Physiological Regulation and Roles in Inflammation and Cancer
- (2012) Helge Wiig et al. PHYSIOLOGICAL REVIEWS
- High Interstitial Fluid Pressure Is Associated with Low Tumour Penetration of Diagnostic Monoclonal Antibodies Applied for Molecular Imaging Purposes
- (2012) Markus Heine et al. PLoS One
- Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting
- (2012) Hiroshi MAEDA PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- A comparative study of PDGFR inhibition with imatinib on radiolabeled antibody targeting and clearance in two pathologically distinct models of colon adenocarcinoma
- (2012) Vineeth S. Rajkumar et al. TUMOR BIOLOGY
- Impact of Drug Conjugation on Pharmacokinetics and Tissue Distribution of Anti-STEAP1 Antibody–Drug Conjugates in Rats
- (2011) C. Andrew Boswell et al. BIOCONJUGATE CHEMISTRY
- Influence of Affinity and Antigen Internalization on the Uptake and Penetration of Anti-HER2 Antibodies in Solid Tumors
- (2011) S. I. Rudnick et al. CANCER RESEARCH
- Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
- (2011) Manish Gupta et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Synthesis and Evaluation of Hydrophilic Linkers for Antibody–Maytansinoid Conjugates
- (2011) Robert Y. Zhao et al. JOURNAL OF MEDICINAL CHEMISTRY
- Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human
- (2011) Dhaval K. Shah et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Antibody-Maytansinoid Conjugates Designed to Bypass Multidrug Resistance
- (2010) Y. V. Kovtun et al. CANCER RESEARCH
- Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
- (2010) N. M. Okeley et al. CLINICAL CANCER RESEARCH
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Effect of Immune Complex Formation on the Distribution of a Novel Antibody to the Ovarian Tumor Antigen CA125
- (2010) C. V. Pastuskovas et al. DRUG METABOLISM AND DISPOSITION
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to Microtubules
- (2010) M. Lopus et al. MOLECULAR CANCER THERAPEUTICS
- Maytansinoid-Antibody Conjugates Induce Mitotic Arrest by Suppressing Microtubule Dynamic Instability
- (2010) E. Oroudjev et al. MOLECULAR CANCER THERAPEUTICS
- Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody−Maytansinoid Conjugates
- (2009) Hans K. Erickson et al. BIOCONJUGATE CHEMISTRY
- P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients
- (2009) Ruoping Tang et al. BMC CANCER
- Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
- (2009) J. P.B. O'Connor et al. CLINICAL CANCER RESEARCH
- Potent antibody drug conjugates for cancer therapy
- (2009) Peter D Senter CURRENT OPINION IN CHEMICAL BIOLOGY
- Elevating Blood Pressure as a Strategy to Increase Tumor-targeted Delivery of Macromolecular Drug SMANCS: Cases of Advanced Solid Tumors
- (2009) Akinori Nagamitsu et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Gaining insights into the consequences of target-mediated drug disposition of monoclonal antibodies using quasi-steady-state approximations
- (2009) Hans Peter Grimm JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- The Pharmacologic Basis for Antibody-Auristatin Conjugate Activity
- (2009) S. C. Alley et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake
- (2009) Jason L.J. Dearling et al. NUCLEAR MEDICINE AND BIOLOGY
- Vascular permeability, vascular hyperpermeability and angiogenesis
- (2008) Janice A. Nagy et al. ANGIOGENESIS
- Direct Visualization of Heterogeneous Extravascular Distribution of Trastuzumab in Human Epidermal Growth Factor Receptor Type 2 Overexpressing Xenografts
- (2008) J. H.E. Baker et al. CLINICAL CANCER RESEARCH
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Effect of antigen turnover rate and expression level on antibody penetration into tumor spheroids
- (2008) M. E. Ackerman et al. MOLECULAR CANCER THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started